ClinicalTrials.gg
RecruitingNCT04179695PARKINSUNUpdated Dec 23, 2025

Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care

An interventional study of Consulting with PARKINSUN as communication aid-tool and Consulting without PARKINSUN as communication aid-tool in Parkinson's Disease, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Parkinson Disease by University Hospital, Lille — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · University Hospital, Lille.

Planned enrollment
2nd of 12
120 · median 55
Started
2020
with 3 others
No phase
5 of 17
1 open now
Registered
12th of 17
by date

Among the 17 studies in Parkinson Disease by University Hospital, Lille, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2020, is one of 5 with no phase, and was the 12th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 17 studies in Parkinson Disease by University Hospital, Lille is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Parkinson Disease by University Hospital, Lille, or all of them as a file.
02

Study summary

PARKINSUN is a new communication aid tool, expected to favor global patient centered care for PD patients during consultation with GPs and neurologists. Two groups of patients will be randomized to use or not PARKINSUN when they consult their physicians every 3 months during 7 months.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Health pathway
  • patient centered care
  • communication aid- tool
  • primary care
  • secondary care
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men and women with all stages of PD
  • Without severe chronic neurological or mental or psychiatric pathology
  • Absence of cognitive impairment affecting autonomy (MDS criteria of dementia and MOCA > 22)
  • able to come (alone or accompanied) to consultation
  • Affiliate or beneficiary of a social security scheme
  • Subject having signed
  • Patient willing to comply with all procedures of the study and its duration

Exclusion criteria

Exclusion Criteria:

  • Administrative reasons: impossibility of receiving informed information, inability to participate in the whole study, absence of coverage by the social security system, refusal to sign consent.
  • Subject under tutelage or curtailer.
  • Subject not fluent in the French language to understand the instructions necessary to carry out the cognitive tests.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    consultation with Parkinsun

    Other: Consulting with PARKINSUN as communication aid-tool

  • Active comparator
    consultation as usual without Parkinsun

    Other: Consulting without PARKINSUN as communication aid-tool

Interventions

  • OtherConsulting with PARKINSUN as communication aid-tool

    Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months

  • OtherConsulting without PARKINSUN as communication aid-tool

    Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months

06

What researchers measure

Primary outcomes

  1. variation of the delta of G-MISS Questionnaire

    Time frame: at 7 months

Secondary outcomes

  1. G-MISS-Questionnaire at the end of each consultation (1 month, 4 months and 7 months)

    Patient's satisfaction will be assessed by the G-MISS-Questionnaire. The G-MISS questionnaire is a standardized and validated tool in French. This questionnaire is taken from the American MISS-21 questionnaire, already used in neurologists to measure the satisfaction of patients with PD, after consultation It is easy to use with an average filling time of 6 minutes.

    Time frame: at the end of each consultation (1 month and 7 months)

  2. Global score of PARKINSUN

    Time frame: at the end of each consultation ((1 month and 7 months)

  3. Individuals scores of PARKINSUN

    Time frame: at the end of each consultation ((1 month and 7 months)

  4. MDS-UPDRS scores

    Time frame: at the end of each consultation ((1 month and 7 months)

  5. PDQ-39 scores 6. Interpersonal Reactivity Index (IRI)

    Time frame: at the end of each consultation ((1 month and 7 months)

  6. Likert Scale

    Time frame: at the end of each consultation (1 month and 7 months)

  7. Interpersonal Reactivity Index (IRI)

    Time frame: at the end of each consultation (1 month and 7 months)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 77 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 27, 2019
StartActual
Jul 21, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04179695
Collaborators
Expert center of Parkinson's Disease (CHU Lille), College of teaching general practitioners (CEMG Lille), Regional Health Agency (ARS), UCB Pharma, Orkyn'
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Jul 21, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

David Devos, MD,PhD
Contact
david.devos@chru-lille.fr
03 20 44 54 49 ext. +33
David Devos
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion